For a new year tried out a new mask, the 3M Aura N95 mask. Wow what a night and day difference. Didn't realize a mask could be this comfortable. Most amazing thing: speech comes through clearly.
My colleague @AbraarKaran is correct: CDC should be pushing better masks like these
These are $3 each and worth it. You can buy a 3pack (or 10pack) and rotate between them. On the 3 days off you let the mask air out to evaporate odors and let any viruses in them die off. More info on this thread.
Not only did HHS and CDC failed to push for mass manufacturing of these masks earlier (a problem since the previous administration when @RickABright was overruled on the matter) but CDC continued to push wrong or obsolete ideas about N95s
These Auras for example are not your granddaddy's cup-style N95s. They fit me without any wiggling and that wasn't true for cup N95s. There's a wide flexible padded strip that's easy to shape around your nose.
CDC has been consistently behind in recommending the right masks. First CDC told people to use cloth and not surgical masks although they were only 50% vs 80% effective in reducing infection from casual exposure. Only a few months ago CDC finally shifted advice to surgical masks
We should move to N95 now not just because the better efficacy (up to 95% block) is useful to slow down transmission by the highly contagious omicron, but also because these new styles are easier to wear right and more comfortable. Here they're modelled by yours truly.
One very nice thing about this design is it doesn't touch your nose and lips. That keeps odors and flavors from accumulating and is also more comfortable.
Given how ineffective cloth masks are and how people don't wear surgical masks correctly (you can always spot someone with their nose poking out from them) it's amazing any studies about mask mandates found differences in case rates, and not surprising that some didn't.
Makes you realize what a missed opportunity it is for CDC not to educate themselves and then the public about more comfortable and effective choices in the market.
And no I'm not getting paid by 3M
And thanks for the multiple people who have pointed out that the bottom strap should go under the ear. I lost track of where the straps went and couldn't feel them. That is the only hard part about putting on the mask — you now have two straps to position.
It's COVID19 so of course we are going to reinvent the wheel, just more slowly
While our attention was diverted by Omicron, FDA approved the viral mutagen molnupiravir (MOV) on the last business day before Christmas. The same time, Merck published that MOV doesn't reduce virus levels in the first 3 days. So patients will be shedding mutated virus for 3 days
I wrote in the Washington Post pointing out that widespread use of the drug increases the risk that we will create new immunoevasive variants. This could come from Delta; it may not be milder like Omicron. Since my piece is no longer browsable, I post it here as a public service
It's not just me. Most scientists or clinicians who know the data are worried. They include @JamesEKHildreth, Defense Health Agency director @peterweina, and former BARDA director @RickABright who were overruled either by FDA or by the prev admin on their MOV concerns
If we can avoid creating worse variants with molnupiravir, COVID19 can finally become like the flu in 2022.
1/n
The SA experience, mirrored in Western countries so far, suggests Omicron IFR is an order of magnitude lower than previous variants. This is due to preexisting immunity and lower virulence of Omicron.
More evidence a booster helps prevent you from catching Omicron. We knew that already from Pfizer but this study looks at risks within households, which is useful info as it provides an absolute rather than relative risk in a common situation
The chart ET posted is confusing, as it normalizes to the "fully vaxxed" state. Leaving aside the heterogeneity of this population (vaxxed at different times, and includes some unknown % with the less effective 1-shot J&J), normalizing to unvaxxed would be better. So I redid it.
As you can see the relative protection from intra-household infection for a boosted person is 48% for Omicron and 84% for Delta vs unvaxxed. 48% is lower than the 70% Pfizer measured, but that's expected for the higher-exposure household setting compared to community transmission
Thanks Dr. Hildreth for speaking out on the dangers of molnupiravir to "the health of the world". We need more people with foresight and integrity like you and @RickABright speaking up
Peter Weina @peterweina, director of the Defense Health Agency, also voted against molnupiravir at the 11/30 AMDAC meeting out of concern for generating new variants. The meeting has been poorly covered in most articles, but here's a good one below
2020.03: Introducing the #coronadeck, explaining what we knew about SARSCoV2 based on its 80% identity to SARSCoV1. Discussed evidence for masks. This was back when CDC and WHO were saying they were ineffective.
2020.04: Wherein I appeared on CBC to advocate for mask wearing, because studies show it works to prevent viral infections. On the other side was a doctor following public health talking points, that masks were ineffective.
ICYMI, on 12/23, the last news day before a long holiday break, FDA approved the viral mutagen molnupiravir as an at-home COVID19 drug. It sounds worrisome because it is. I wrote in the @washingtonpost that immunoevasive variants could arise from its use. washingtonpost.com/outlook/2021/1…
If molnupiravir gives rise to enhanced mutants of SARSCoV2, it will prolong the pandemic and cause countless deaths and needless suffering. Yet it's only 30% effective in preventing hospitalization, similar to generic antidepressant and far worse than the 89% of other antivirals.
FDA knew of the concerns about mutant viruses escaping from patients taking MOV. This was discussed at the AMDAC FDA advisors meeting 1 month ago and contributed to the 10 no votes. It was revealed Merck didn't know what mutations occur in patients and when viruses are cleared.